All In Biotech

Drug Trial Radar · NCT07482176

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 534 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

534

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Nov 15, 2027

Study completion Oct 20, 2031

Sponsor

Lead sponsor
Adverum Biotechnologies, Inc.Industry
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)
  • Wet AMD

Interventions

  • Ixo-vecGenetic

    Ixo-vec will be administered intravitreally.

  • AfliberceptDrug

    Aflibercept will be administered intravitreally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change from Baseline in BCVA Based on an Average at Weeks 52 and 56Time frame: Baseline, Week 52 and Week 56

Locations

79 sites in 1 country. Site status is shown where the registry gives one.

  • Adverum Clinical Site 245

    Mesa, Arizona · Recruiting

  • Adverum Clinical Site 126

    Phoenix, Arizona · Recruiting

  • Adverum Clinical Site 178

    Phoenix, Arizona · Recruiting

  • Adverum Clinical Site 223

    Phoenix, Arizona · Recruiting

  • Adverum Clinical Site 229

    Scottsdale, Arizona · Recruiting

  • Adverum Clinical Site 242

    Sun City, Arizona · Recruiting

  • Adverum Clinical Site 198

    Springdale, Arkansas · Recruiting

  • Adverum Clinical Site 109

    Bakersfield, California · Recruiting

  • Adverum Clinical Site 100

    Beverly Hills, California · Recruiting

  • Adverum Clinical Site 201

    Campbell, California · Recruiting

  • Adverum Clinical Site 172

    Encino, California · Recruiting

  • Adverum Clinical Site 169

    Fullerton, California · Recruiting

  • Adverum Clinical Site 224

    Huntington Beach, California · Recruiting

  • Adverum Clinical Site 130

    Poway, California · Recruiting

  • Adverum Clinical Site 215

    Redlands, California · Recruiting

  • Adverum Clinical Site 140

    Sacramento, California · Recruiting

  • Adverum Clinical Site 212

    Sacramento, California · Recruiting

  • Adverum Clinical Site 175

    Santa Barbara, California · Recruiting

  • Adverum Clinical Site 202

    Torrance, California · Recruiting

  • Adverum Clinical Site 189

    Walnut Creek, California · Recruiting

  • Adverum Clinical Site 200

    Denver, Colorado · Recruiting

  • Adverum Clinical Site 116

    Denver, Colorado · Recruiting

  • Adverum Clinical Site 165

    Waterford, Connecticut · Recruiting

  • Adverum Clinical Site 124

    Deerfield Beach, Florida · Recruiting

  • Adverum Clinical Site 184

    Deerfield Beach, Florida · Recruiting

  • Adverum Clinical Site 176

    Fort Lauderdale, Florida · Recruiting

  • Adverum Clinical Site 221

    Fort Myers, Florida · Recruiting

  • Adverum Clinical Site 236

    Gainesville, Florida · Recruiting

  • Adverum Clinical Site 214

    Lakeland, Florida · Recruiting

  • Adverum Clinical Site 168

    Miami Springs, Florida · Recruiting

  • Adverum Clinical Site 213

    Orlando, Florida · Recruiting

  • Adverum Clinical Site 206

    Plantation, Florida · Recruiting

  • Adverum Clinical Site 183

    South Miami, Florida · Recruiting

  • Adverum Clinical Site 120

    St. Petersburg, Florida · Recruiting

  • Adverum Clinical Site 148

    Tampa, Florida · Recruiting

  • Adverum Clinical Site 238

    Winter Haven, Florida · Recruiting

  • Adverum Clinical Site 182

    Augusta, Georgia · Recruiting

  • Adverum Clinical Site 246

    Chicago, Illinois · Recruiting

  • Adverum Clinical Site 179

    Oak Forest, Illinois · Recruiting

  • Adverum Clinical Site 207

    Oak Park, Illinois · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.